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The expression of human Parvovirus B19 nonstructural protein 1 (NS1) induces cell cycle arrest at the G1 phase and is accompanied by
increased expression of the cyclin-dependent kinase inhibitor, p21/WAF1. Here, we provide direct evidence that NS1 mediates the
transactivation of p21/WAF1. Up-regulation of p21/WAF1 by wild-type NS1 but not an NS1 mutant deleted of its NTP binding motif was
observed. We also demonstrated that the wild-type NS1 is unable to induce G1 arrest in p21-deficient cells. Using reporter plasmids
containing various mutants of the p21/WAF1 promoter, luciferase assay further revealed that the binding sites of the promoter to the
transcription factor Sp1 are critical for NS1-mediated transactivation. Indeed Sp1 interacts only with the wild-type NS1 but not the NS1
mutant. These results indicate a cooperative contribution of NS1 and Sp1 to the transactivation of p21/WAF1, which leads to G1 arrest.
D 2004 Elsevier Inc. All rights reserved.
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Parvovirus B19 is the only pathogenic member of the
Parvoviridae in humans. There are five major clinical
manifestations related to B19 virus infection: aplastic crisis
in patients with hemolytic anemia, erythema infectiosum,
arthralgia/arthritis, persistent infections manifesting as
chronic anemia in immunocompromised patients, and after
maternal infection, nonimmune hydrops fetalis, which can
lead to intrauterine fetal death (Anderson et al., 1983, 1988;
Bradley et al., 1987; Brown et al., 1994; Kurtzman et al.,
1987). B19 virus is a potent inhibitor of erythroid cell
differentiation and is cytotoxic for erythroid precursor cells
(Ozawa et al., 1987), and most B19-associated clinical0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.09.008
$ Activation of p21/WAF1 by B19 NS1.
* Corresponding author. Department Microbiology and Immunology,
Graduate School of Medicine, Tohoku University, 2-1 Seiryo-machi, Aoba-
ku, Sendai, Miyagi, 980-8575, Japan. Fax: +81 22 717 8097.
E-mail address: sugamura@mail.tains.tohoku.ac.jp (K. Sugamura).manifestations are closely related to damage of erythroid
precursor cells (Brown et al., 1994).
A nonstructural protein 1 (NS1) is encoded by the left
side of the B19 genome and appears on Western blots as a
doublet with apparent molecular weights of 70 and 77 kDa
(Morita et al., 2001). NS1 is synthesized from a strong left
side promoter at map unit 6 (p6), which is the only
functional promoter in the B19 genome. NS1 is cytotoxic,
and NS1-transfected cells and B19 virus-infected cells have
ultrastructural features typical of apoptosis (Morey et al.,
1993; Yaegashi et al., 1999). NS1 is also essential for the
replication of viral DNA and the activation of the B19 p6
promoter (Brown et al., 1994) and has a positive feedback
effect on the activity of the p6 promoter (Doerig et al.,
1990). Such effects of NS1 on p6 promoter activity have
been suggested to be mediated by a multicomponent
complex that combines NS1 with ATF, NF-nB/cRel, and
cellular GC-box binding factors (Gareus et al., 1998).
In another Parvovirus, the minute virus of mice (MVM)
transactivation by NS1 is dependent on the presence of04) 493–504
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promoter (Ahn et al., 1992). Sp1, a transcriptional factor
that is known to bind GC box elements, plays a key role in
the activation of a variety of viral and cellular gene
promoters (Suske, 1999). In this context, an interaction
between MVM NS1 and Sp1 is reportedly required to
stimulate transcription of the p38 promoter, which contains
an Sp1 binding site (Krady and Ward, 1995).
Nonstructural protein genes are highly homologous
among the Parvoviruses, including the B19 virus, MVM,
and adeno-associated virus (AAV). MVM and AAV each
express nonstructural protein, NS1 and Rep, which are
homologous proteins, respectively, that are required for
viral DNA replication and transcriptional regulation (Im
and Muzyczka, 1990; Jindal et al., 1994). Moreover, the
genes that encode these proteins contain the A-type
consensus sequence [(G/A) XXXXGK (S/T)], referred to
as a nucleoside triphosphate (NTP) binding motif, which
was originally identified in the large T antigens of
Polyomaviruses and E1 proteins of Papillomaviruses
(Bradley et al., 1987). Mutations in the NTP binding
motifs of MVM NS1 and AAV Rep affect their functions,
which include ATP binding, ATPase and helicase enzy-
matic activities, transactivation, and DNA replication
(Horer et al., 1995; Jindal et al., 1994). The DNA- and
RNA-dependent nucleoside triphosphatases are key
enzymes in the biochemical pathways of replication, repair,
recombination, transcription, and translation of a variety of
cellular and viral genes (Momoeda et al., 1994). B19 virus
NS1 also contains an NTP binding motif in the middle of
the sequence, which has been shown to harbor at least a
helicase activity (Astell et al., 1987; Raab et al., 2002).
Furthermore, an NS1 mutant in which lysine 334 in the
NTP binding motif is converted to glutamate loses its
cytotoxic activity (Momoeda et al., 1994).
Infection by Parvoviruses such as B19, AAV, and MVM
induces cell cycle arrest of their target cells (De Beeck et al.,
2001; Morita et al., 2001, 2003; Winocour et al., 1988). In
AAV, the growth of virus-infected cells is inhibited by the
accumulation of G2-phase cells, in which the AAV hairpin
DNA plays a critical role (Raj et al., 2001). MVM-infected
cells are known to be arrested at the G1, S, and G2 phases
(De Beeck et al., 2001; Op De Beeck and Caillet-Fauquet,
1997). We have also demonstrated that B19 virus infection
induces cell cycle arrest at the G1 and G2 phases; the G1
arrest is mediated by NS1, and the G2 arrest is mediated by
a different mechanism since it can be induced by an
inactivated B19 virus that cannot express NS1 (Morita et al.,
2001, 2003). NS1-transfected cells that arrest at the G1
phase express p21/WAF1, a cyclin-dependent kinase (CDK)
inhibitor (Morita et al., 2003). p21/WAF1, which was
initially identified as a target gene for p53 transactivation
(el-Deiry et al., 1993), is involved in the suppression of G1
to S-phase cell cycle progression through its binding to G1
cyclin/CDK complexes (Harper et al., 1993). However,
there is accumulating evidence for a p53-independenttranscriptional activation of p21/WAF1, in which the
proximal region of the p21/WAF1 promoter (base pairs
210 to +1) is a major responsive element containing
several GC-rich motifs that serve as binding sites for
members of the Sp1 family of transcription factors (Nakano
et al., 1997). Here we demonstrate that a complex consisting
of NS1 and Sp1 transactivates p21/WAF1, resulting in cell
cycle arrest at the G1 phase.Results
An NTP-binding-defective mutant of NS1 is unable to
induce cell cycle arrest at the G1 phase or expression of
p21/WAF1
We previously reported that in some cell lines treated
with the mitotic inhibitor, paclitaxel, the transfection of
NS1, as well as B19 virus infection induce cell cycle arrest
at the G1 phase as well as the expression of p21/WAF1
(Morita et al., 2003). To address the functional significance
of NS1 in cell cycle arrest and p21/WAF1 expression, we
constructed an NS1 mutant expression vector, pMP6-NS1-
KE, that has a single amino acid substitution in the NTP
binding motif. The percentages of 293T cells arrested in the
G1 phase were 40.0%, 16.3%, and 16.3% for cells trans-
fected with the wild-type NS1, NS1-KE, and the control
vector, respectively (Fig. 1A). Similar results were obtained
using UT7/Epo-S1 cells (Fig. 1B). These results indicated
that the NS1-KE mutant lost its ability to induce cell cycle
arrest at the G1 phase. Next, we examined the expression
levels of NS1 and p21/WAF1 by Western blotting. The
expression level of NS1-KE was similar to that of the wild-
type NS1; however, the expression levels of p21/WAF1
were clearly different in the cells transfected with the wild-
type versus the mutant NS1: the NS1-KE mutant suppressed
by approximately 40% the expression of p21/WAF1, as
compared to wild-type NS1 (Fig. 1C). The transfection
efficiencies of the wild-type NS1, NS1-KE, and the control
vectors ranged from 60% to 80% (data not shown). These
results suggest that the intact NTP binding motif of NS1
is essential to induce G1 arrest and the expression of
p21/WAF1.
Small interfering RNAs (siRNAs) to p21/WAF1 impair G1
arrest induced by NS1
To investigate the role of p21/WAF1 in NS1-induced G1
arrest, we examined the effect of pMACS–H2Kk–siRNA–
p21, an siRNA vector, which suppresses p21/WAF expres-
sion, on the G1 arrest. Following introduction of the siRNA
vector into 293T cells, enrichment of H2Kk-positive cells
was done by AutoMACS machine. There was no significant
bias of cell cycle distribution upon siRNA–p21 transfection
(data not shown). H2Kk-positive 293T cells were further
transfected with NS1 or control vectors followed by
Fig. 1. The NS1-KE mutant did not induce cell cycle arrest at the G1 phase. (A and B) The 293T cells (A) and UT7/Epo-S1 cells (B) were transfected with NS1
(upper panels), NS1-KE (middle panels), or control vector (lower panels) and incubated for 48 and 24 h, respectively. They were then treated (right panels) or
not treated (left panels) with paclitaxel, a mitotic inhibitor, for 24 h. Subsequently, they were stained with PI to detect the DNA content and loaded on a FACS
caliber. (C) The expressions of NS1, NS1-KE, and control vector were detected by Western blotting with anti-NS1, and p21/WAF1 and a-tubulin were detected
with their specific antibodies in the lysates of 293T cells transfected as described above. The percentage of p21/WAF1 expression level is shown below the
middle panel.
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p21/WAF1 expression in H2Kk-positive 293T cells (Fig.
2A, approximately 50% suppression). Furthermore, G1
arrests of NS1-transfected cells showed 25.6% in siRNA–
p21-transfected cells and 39.5% in siRNA–control-trans-
fected cells (Fig. 2B). We obtained similar results in
triplicate experiments (Fig. 2C). These results suggest that
the down-regulation of p21/WAF expression by the siRNA
leads to a decrease of the NS1-induced G1 arrest.
NS1-mediated p21/WAF1 promoter activation
NS1 transactivates the p21/WAF1 promoter, for which
the Sp1 binding sites of the promoter are indispensable. We
next investigated the mechanism by which NS1-induced G1
arrest through p21/WAF1. Hence, the effects of NS1 on p21/
WAF1 promoter activity were examined by transient trans-
fection using a luciferase assay. Forty-eight hours after the
transfection, NS1 had induced a 3.8-fold increase in the
luciferase activity of the full-length wild-type p21/WAF1
promoter, pWWP, as compared with the control vector (Fig.
3B), indicating that NS1 transactivates the p21/WAF1
promoter. We next determined the NS1 responsive ele-
ment(s) in the p21/WAF1 promoter using a series of p21/WAF1 promoter mutants: pWP124, in which the two p53
binding sites were deleted but all six Sp1 binding sites
remained; pWP101, in which the Sp1-1 and Sp1-2 sites
were deleted; and pWPdel–SmaI, in which the Sp1-1 to
Sp1-4 sites were deleted (Fig. 3A). NS1 induced 4.6-, 3.5-,
and 1.6-fold increases in the luciferase activities of
pWP124, pWP101, and pWPdel–SmaI, respectively, as
compared with the control vector (Fig. 3B). The NS1-KE
mutant showed negligible transactivation of any p21/WAF1
promoter (data not shown). The basal promoter activities of
pWP124, pWP101, and pWWP were not significantly
different, whereas pWPdel–SmaI showed a decreased
promoter activity at 13.4% of pWWP (Fig. 3B). Taken
together, these results indicated that NS1-mediated p21/
WAF1 promoter activation requires the region containing
the Sp1-3, Sp1-4, and Sp1-5-6 sites and the TATA element.
pWP101 was further mutated at the Sp1 sites and the
TATA element. These constructs were termed pWP101-
mtSp1-3, pWP101-mtSp1-4, pWP101-mtSp1-5-6, and
pWP101-mtTATA, respectively (Fig. 3C). In the NS1-
induced luciferase assays, pWP101-mtSp1-3 showed an
activation of only 1.1-fold of control levels, compared with
the 3.5-fold activation of pWP101, and the basal activity
of pWP101-mtSp1-3 was 8.2% of that of pWP101 (Fig.
Fig. 2. Small interfering RNAs (siRNAs) to p21/WAF1 impair G1 arrest
induced by NS1. The 293T cells were transfected with pMACS–H2Kk–
siRNA–p21 (p21/WAF1 siRNA) or pMACS–H2Kk–siRNA–control (empty
vector). H2Kk-positive cells were transfected with NS1 or control vector as
described under Materials and methods. (A) The p21/WAF1 protein level in
nuclear extracts from NS1-transfected cells were detected using anti-p21/
WAF1 antibody, cells transfected with control vector (left), or siRNA–p21
(right). (B) The 293T cells transfected with siRNA vectors were transfected
with NS1 (upper panels) or control vector of NS1 (lower panels) and
incubated for 24 h, respectively. They were then treated with paclitaxel for
another 24 h. Cells were stained with PI to detect the DNA content by a
FACS caliber. (C) Percentages of the cells at the G1 phase in panel B were
counted.
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of pWP101; however, the NS1-induced luciferase activity
was 2.8-fold of control levels (Fig. 3C). In contrast, the
basal activities of pWP101-mtSp1-5-6 and pWP101-
mtTATA were 0.1% that of pWP101, that is, background
level, and the NS1-induced activation was entirely
abolished in these constructs (Fig. 3C). From these results,
we concluded that the Sp1-3 site but not the Sp1-4 site is
the main NS1-responsive element for regulating trans-
activation, and that the Sp1-5-6 site and TATA element are
indispensable for the basal promoter activity of the p21/
WAF1 promoter.
Since the two Sp1 sites play critical roles in the NS1-
mediated transactivation, we performed an EMSA using
probes for wild-type Sp1-3, Sp1-3wt, and a mutant Sp1-3,
Sp1-3mt, and nuclear extracts from 293T cells transfected
with NS1, NS1-KE, and control vector (Fig. 4). The EMSA
with the Sp1-3wt probe revealed three specific bands that
we refer to as the fast, slow, and slowest bands. In EMSAs
with nuclear extracts of cells transfected with NS1 and NS1-
KE, the intensities of the three bands were very similar to
those obtained using nuclear extracts from cells transfected
with the control vector (Fig. 4, lanes 1–3). When the nuclear
extracts were pretreated with the anti-Sp1 antibody, theintensity of the slowest band decreased significantly and a
supershifted band became detectable, but the slow and fast
bands changed little (Fig. 4, lanes 4–6). In contrast, when
the nuclear extracts were pretreated with the anti-Sp3
antibody, the slow and fast bands decreased and faint
supershifted bands were detectable, but the slowest band
changed little (Fig. 4, lanes 7–9). Pretreatment with both
anti-Sp1 and anti-Sp3 antibodies induced significant reduc-
tions in all three bands (Fig. 4, lanes 10–12); the three bands
were undetectable when Sp1-3mt was used as a probe (Fig.
4, lanes 13–15). Pretreatment with the anti-NS1 antibody
had no effect on the three bands (data not shown). These
results suggest that the slowest bands corresponded to the
probes bound to Sp1, and the slow and fast bands
corresponded to probes bound to Sp3, and that NS1 does
not affect the Sp1 binding affinity to the Sp1-3 site in the
p21/WAF1 promoter. We also confirmed that NS1 has no
effect on the binding of Sp1 and Sp3 to the Sp1-5-6 site
(data not shown).
NS1-mediated transactivation of the p21/WAF1 promoter is
up-regulated by Sp1 and CBP
Since the Sp1-3 and Sp1-5-6 sites played important roles
in the p21/WAF1 promoter activation induced by NS1, we
examined whether Sp1 and Sp3 are involved in the NS1-
mediated transactivation of the p21/WAF1 promoter. The
coexpression of Sp1 with NS1 significantly enhanced the
expression of the wild-type p21/WAF1 reporter plasmid,
pWWP, in a dose-dependent manner (Fig. 5A). In contrast,
the activities of pWWP were unchanged by varying doses of
Sp3. Furthermore, the NS1-mediated transactivation of the
p21/WAF1 promoter was also inhibited by Sp3 (Fig. 5B).
These results suggest that Sp1 but not Sp3 is a critical
transcription factor in the p21/WAF1 promoter activation
mediated by NS1 in 293T cells.
p300/CBP has been shown to interact functionally with
a number of transcriptional activators including Sp1,
CREB, NF-nB, p53, and others (Chan and La Thangue,
2001; Fang and Lu, 2002). We next addressed the possible
involvement of CBP in the NS1-mediated p21/WAF1
promoter activation. The coexpression of CBP with NS1
significantly enhanced the expression of pWWP-Luc in a
dose-dependent manner (Fig. 5C). We further examined
the effects of CBP on the p21/WAF1 mutant reporter
plasmids, pWP124 and pWPdel–SmaI. The luciferase
assay results of pWP124 were similar to those of pWWP
(Fig. 5D), whereas neither NS1 nor CBP induced
expression of pWPdel–SmaI (data not shown). These
results suggest that CBP contributes to the NS1-mediated
activation of p21/WAF1 transcription, for which the Sp1
sites are also required.
To determine whether Sp1 acts as a mediator of the NS1-
induced transactivation, we used a system in which Sp1 was
fused to the DNA binding domain of the bacterial tran-
scriptional factor GAL4. Consequently, the ability of the
Fig. 3. Sp1 binding sites are critical for NS1-mediated p21/WAF1 promoter activation. (A) Genomic sequence of the p21/WAF1 promoter region. The
transcription start site is indicated by the number 0 above the sequence. The multiple Sp1 binding sites termed Sp1-1, Sp1-2, Sp1-3, Sp1-4, and Sp1-5-6 are
indicated by underlining. The TATA box is indicated by bold letters and underlining. The enzyme site of pWPdel–SmaI is indicated. (B) Luciferase analyses
with a series of 5Vdeletion mutants of the p21/WAF1 promoter. The 293T cells were transiently cotransfected with the constructed plasmids, pWWP, pWP124,
pWP101, and pWPdel–SmaI, or the control vector (white bar), or NS1 (black bar), and the luciferase activities were analyzed after incubating the transfected
cells for 48 h. Relative luciferase activities are shown as the raw light units (RLU) in cell lysates per 1 mg of protein, and the fold inductions of luciferase
activities were calculated in comparison to the luciferase activity induced by the control vector. (C) Luciferase analyses with mutants containing point
mutations in the Sp1 sites on the p21/WAF1 promoter. As shown on the left, four mutants are identical to the wild-type pWP101 except for the mutations
indicated. Luciferase activities were analyzed in a similar manner to panel B.
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GAL4 DNA binding site in both the presence and absence
of NS1 could be measured. In this way, Sp1 up-regulates a
luciferase reporter plasmid, pG5-Luc, which has five
consensus GAL4 DNA binding sites, in a dose-dependent
manner. Furthermore, the coexpression of Sp1 with NS1
significantly enhanced the activity of the luciferase reporter
plasmid (Fig. 5E). This data suggested that the transcrip-
tional activity of Sp1 is generally enhanced by coexpression
of NS1.
To explore whether there is a cooperative function of Sp1
and CBP in the NS1-mediated p21/WAF1 promoter
activation, we carried out p21/WAF1 luciferase assays
using 293T cells transfected with NS1, Sp1, Sp3, and
CBP. The combination of NS1, Sp1, and CBP showed thehighest activity, 9.2-fold, and the combination of NS1, Sp3,
and CBP showed a lower activity, 2.7-fold, than the
previous combination (Fig. 5F, lanes 13 and 14). The
addition of Sp3 to the combination of NS1 and Sp1 did not
enhance the luciferase activity further (Fig. 5F, lanes 6 and
12). These data indicated that CBP and Sp1 but not Sp3
synergistically participate in the NS1-mediated p21/WAF1
transcriptional activation.
Direct binding of NS1 to Sp1
Since NS1, Sp1, and CBP are cooperatively involved in
the transactivation of the p21/WAF1 promoter through a
minimal region containing the Sp1 sites, we examined
complex formation among the three molecules. The 293T
Fig. 4. EMSAs for the Sp1 binding sites on p21/WAF1. EMSAs were
carried out with nuclear extracts of 293T cells transfected with NS1, NS1-
KE, or control vector. (A) End-labeled oligonucleotides were used for the
Sp1-3wt probe (lanes 1–12) and Sp1-3 mutant probe (lanes 13–15). No
antibody (lanes 1–3 and 13–15), the anti-Sp1 antibody (lanes 4–6), and the
anti-Sp3 (lanes 7–9) and anti-Sp1+ anti-Sp3 (lanes 10–12) antibodies were
used. The positions of Sp1 and Sp3 are indicated on the left. S-S: Sp1
indicates supershifted band of Sp1.
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and CBP, and their nuclear extracts were immunoprecipi-
tated and immunoblotted with each antibody. In cotrans-
fected cells, NS1 and Sp1 were co-immunoprecipitated
(Fig. 6A), indicating a direct interaction between NS1 and
Sp1. A small amount of NS1 was co-immunoprecipitated
with Sp1 in lysates from cells transfected with NS1 alone
(Fig. 6A), suggesting an interaction between NS1 and
endogenous Sp1. On the other hand, the co-immunopre-
cipitation of NS1 and Sp3 was not seen in lysates from
cells cotransfected with both constructs (Fig. 6B). NS1 and
CBP did not co-immunoprecipitate with each other either
(data not shown). These results showed that NS1 interacts
with Sp1, but not Sp3 or CBP. We also examined whether
the NS1-KE mutant interacts with Sp1. In contrast to wild-
type NS1, the NS1-KE mutant did not co-immunoprecipi-Fig. 5. NS1-mdiated activation of the p21 promoter in luciferase assays.
(A and B) The 293T cells were cotransfected with the indicated amounts of
the Sp1 (pEVR2/Sp1) or Sp3 (pRc/CMV/Sp3) expression construct and
the p21/WAF1 luciferase reporter plasmid (pWWP) and pMP6-NS1 (NS1)
or pMP6 (control). (C and D) The indicated amounts of HA-tagged CBP
expression construct (pRc/RSV/CBP) were cotransfected with pWWP or
pWP124 containing all six Sp1 binding sites and pMP6-NS1 or pMP6. (E)
The 293T cells were cotransfected with the indicated amounts of the pM-
Sp1 (GAL4-Sp1) expression construct, the luciferase reporter plasmid
containing five consensus GAL4 DNA binding sites (pG5-Luc), and
pMP6-NS1 or pMP6. (F) According to the combinations of the indicated
plasmids, 293T cells were transfected with 10 ng of pWWP, 1 Ag of
pMP6-NS1, 200 ng of pEVR2/Sp1, 200 ng of pRc/CMV/Sp3, and/or 1 Ag
of pRc/RSV/CBP. The total amounts of plasmid were adjusted by adding
empty control vectors. Luciferase activities were analyzed after incubation
for 48 h. The relative luciferase activities are shown as raw light units
(RLU) in cell lysates per 1 mg of protein, and fold inductions that are
compared with the four transfected control vectors (lane 1) are indicated
below.
Fig. 6. Co-immunoprecipitation of NS1 and Sp1. Nuclear extracts of 293T
cells transfected with the indicated combinations of NS1, NS1-KE, and Sp1
were immunoprecipitated then immunoblotted with antibodies against NS1
and Sp1.
Fig. 7. The NS1-induced G1 arrest is completely abrogated in p21-deficient
cells. (A) HCT116p53KD, p21+/+ cells or HCT116p53KD, p21/ cells were
transfected with NS1 (upper panels) or control vector of NS1 (lower panels)
and incubated for 24 h, respectively. They were then treated with paclitaxel
for 24 h. Subsequently, they were stained with PI to detect the DNA content
and loaded on a FACS caliber. (B) At the indicated times after paclitaxel
treatment, percentages of the cell at the G1 phase were counted. Cell lines
were HCT116p53KD, p21+/+ cells transfected with control vector (closed
diamonds), or with NS1 vector (closed squares), and HCT116p53KD, p21/
cells transfected with control vector (open diamonds), or with NS1 vector
(open squares). (C) Percentages of the cells at the G1 phase in panel Awere
counted.
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cotransfected cells (Fig. 6C). These results implied that
the NS1-KE mutant, in which the NTP binding motif was
deleted, could not interact directly with Sp1, suggesting
that the formation of a complex containing NS1 and Sp1 is
indispensable for the transactivation of the p21/WAF1
promoter.
p21/WAF1 is indispensable to the NS1-induced G1 arrest
The luciferase assay showed that NS1-induced trans-
activation of the p21/WAF1 promoter requires the
presence of Sp1 binding sites, Sp1-3 and Sp1-5-6, but
not p53 binding sites (Fig. 3B). To confirm the in-
dispensable role of the NS1 and Sp1 complex in induction
of p21/WAF1, we first established a p53 knock-down
and p21-deleted cell line, HCT116p53KD, p21/, by using
pRNAT-U6.1/Neo-p53-1. The NS1-induced G1 arrest was
33.2% in HCT116p53KD, p21+/+ cells, and 13.9% in
HCT116p53KD, p21/, respectively (Fig. 7A). The cell
population in the G1-phase of HCT116p53KD, p21/ cells
significantly decreased in a time-dependent manner, but littlein HCT116p53KD, p21+/+ cells (Fig. 7B). We further showed
that the G1 arrest in HCT116p53KD, p21/ cells is mediated
by the wild-type NS1, but not NS1-KE mutant or control
vector (Fig. 7C). The accumulation of p21/WAF1 expression
in HCT116p53KD, p21+/+ cells transfected with NS1 was
confirmed to be much higher than those transfected with
control or NS1-KE (data not shown). Thus, p21/WAF1 plays
a critical role in the NS1-mediated induction of G1 arrest.Discussion
We previously reported that B19 virus can induce not
only G2 arrest but also G1 arrest, and NS1, a nonstructural
protein of B19 virus, plays an important role in the
induction of G1 arrest accompanied by the expression of
p21/WAF1, a CDK inhibitor (Morita et al., 2003). However,
it remained unclear whether NS1 directly contributes to the
expression of p21/WAF1. In the present study, we first
showed that the NS1-KE mutant, which has a point
mutation in the NTP binding motif, does not induce G1
arrest or the accumulation of p21/WAF1. Second, wild-type
NS1 transactivated the p21/WAF1 promoter via a minimal
A. Nakashima et al. / Virology 329 (2004) 493–504500region consisting of the Sp1 binding sites and the TATA
element, but the NS1-KE mutant, had no such trans-
activating activity. NS1 but not the NS1-KE mutant bound
directly to Sp1. Finally, NS1-induced G1 arrest was
abrogated in a p21-deficient cell line. Since the accumu-
lation of p21/WAF1 is generally known to induce G1 arrest
(Harper et al., 1993), we conclude that Sp1 combining with
NS1 contributes to the activation of the p21/WAF1
promoter, which results in the accumulation of p21/WAF1
to induce cell cycle arrest at the G1 phase. Moreover, these
suggest that the NTP binding motif of NS1 is indispensable
for its interaction with Sp1 and its transactivation of the p21/
WAF1 promoter.
Transfection of NS1 reportedly induces a cytotoxicity,
but not of NS1-KE mutant (Momoeda et al., 1994). We have
shown that NS1 has a potent ability to induce G1 arrest,
resulting in growth arrest (Morita et al., 2003). In this study,
an NS1-KE mutant was unable to undergo cell cycle arrest,
which may reflect the abolishment of the cytotoxicity. These
results suggest that the NTP binding motif of NS1 is
important for the induction of cell cycle arrest at the G1
phase, which may be responsible for its cytotoxic effect.
The functional significance of NS1 has been investigated
in the transactivation of the viral p6 promoter; NS1
transactivates the p6 promoter, and the binding sites for
ATF/CREB, NF-nB/cRel, and GC-box are critically
involved in this transactivation (Gareus et al., 1998). Since
the GC-boxes in the p6 promoter correspond to Sp1 binding
sites (Dynan and Tjian, 1983), a direct interaction between
NS1 and Sp1 is also thought to be important for the p6
transactivation. In the regulation of cellular gene expression,
Sp1 is also known to exert its transcriptional properties by
direct interaction with basal transcriptional factors and
transcriptional activators (Suske, 1999). Hence, the cellular
target genes for Sp1 are expected to be activated by NS1.
We demonstrated here that a complex of NS1 and Sp1
contributes to the expression of a cellular gene, p21/WAF1.
With respect to binding of NS1 to Sp1 family members, not
only Sp1 but also Sp3 was revealed to bind NS1 in a
previous report by using an ELISA assay (Raab et al.,
2002). However, we here demonstrate that NS1 is able to be
co-immunoprecipitated with Sp1 but not Sp3, suggesting
that Sp1 is preferentially involved in NS1-induced p21/
WAF1 expression. This discrepancy of NS1 binding to the
Sp1 family members may be due to the difference in assay
systems. Since the co-immunoprecipitation assay reflects
quantitative rather than qualitative binding as compared
with the ELISA assay, our present study indicates more
precise binding affinities between NS1 and Sp1 family
members. In addition, an NS1-KE mutant, which is unable
to undergo cell cycle arrest and to transactivate p21/WAF1
promoter, did not bind to Sp1. In fact, cotransfection of NS1
with Sp1 induced a significant level of p21/WAF1 promoter
activation but not with Sp3. Similarly, Sp1 involvement was
shown in promoter activation of p21/WAF1 and type II
procollagen gene (Billon et al., 1999; Chadjichristos et al.,2002; Kardassis et al., 1999). Taken together, the direct
binding of NS1 to Sp1 is critical for transactivation of p21/
WAF1 promoter.
We demonstrated that an Sp1-3wt probe containing the
TCCCGCCT motif is the main NS1-responsive element for
transactivation of p21/WAF1, and that NS1 does not alter
the binding of Sp1 and Sp3 to the motif. Though we could
not detect NS1 binding to the Sp1-3wt probe, it may be due
to a possibility that our NS1 mAb, which recognizes the C-
terminal region of NS1, is unable to bind NS1, which
preforms a complex with Sp1 on p21 promoter. It is still
unclear how the complex of NS1 and Sp1 affects the p21/
WAF1 promoter. In this context, B19 NS1 is known to
interact directly with the region D of its own p6 promoter,
and the region D contains the entirely same motif as Sp1-
3wt probe, but NS1 does not inhibit the binding of Sp1 to
the motif (Raab et al., 2002). On the other hand, MVM NS1
reportedly required Sp1 for its binding to the own viral
promoter (Krady and Ward, 1995). Taken together, we
speculate that not only Sp1 but also NS1 binds to Sp1-3
element of the p21/WAF1 promoter, but the NS1 binding to
the element may be too faint to be detected in our EMSA
assay. Alternatively, NS1 may interact with Sp1-3wt
element through binding to Sp1.
CBP and p300 are transcriptional cofactors, which
contain highly conserved amino acid sequences and appear
to regulate a variety of gene expressions (Goodman and
Smolik, 2000). p300 is known to contribute to the Sp1-
induced activation of p21/WAF1 gene expression (Billon et
al., 1999; Xiao et al., 2000), and both p300 and CBP have
histone acetyltransferase (HAT) activity, which is generally
important for the transcriptional regulation of cellular genes
(Chan and La Thangue, 2001). We revealed here that the
NS1-mediated transactivation of p21/WAF1 promoter is
enhanced by CBP. Since we did not detect the direct
interactions between CBP and NS1, or between CBP and
Sp1 in the presence of NS1 (data not shown), the
mechanism remains unknown but one can speculate that
CBP may be involved in the NS1-mediated transactivation
of p21/WAF1 promoter through activation of Sp1. Alter-
natively, since Sp1 is known to interact with the hTAFII 130
protein, a cofactor in the TFIID complex that also has HAT
activity (Tanese et al., 1996), the hTAFII 130 protein may be
replaced by overexpressed CBP in our assay system for the
NS1-mediated transactivation of p21/WAF1 promoter.
Nevertheless, NS1 is predicted to initiate transcription of
p21/WAF1 gene through interaction with Sp1 that in turn
possibly activates HAT.
Since the deletion mutants of the carboxy-terminus of
MVM NS1, which have an intact NTP binding motif, are
unable to transactivate its own p38 promoter (Legendre
and Rommelaere, 1994), both the NTP binding motif and
the carboxy-terminus of MVM NS1 play critical roles in
this transactivation. A similar pattern seen in MVM NS1
can be addressed to B19 NS1, so that not only the NTP
binding motif but also the carboxy-terminus region may be
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cellular target gene, p21/WAF1. Defining molecule(s) that
interact with the carboxy-terminus region of NS1 may
provide critical information about the functional signifi-
cance of NS1 in G1 arrest and the cytotoxicity of B19
virus-infected cells.
We previously revealed that inactivated B19, which
expresses little NS1, can induce G2 arrest but not G1 arrest
(Morita et al., 2003), and here that NS1 has inducing ability
for G1 arrest but not G2 arrest. These observations suggest
that NS1 and other viral factors including hairpin structures
have distinct roles in regulation of cell cycle arrests.
Furthermore, we demonstrated the significant role of p21/
WAF1 in the NS1-induced G1 arrest using a siRNA vector
and a p21-deficient cell line. In addition, MVM NS1-
induced G2 arrest depends on p21/WAF1 (De Beeck et al.,
2001), and the sustenance of the G2 arrest induced by DNA
damage requires p21/WAF1 (Bunz et al., 1998). These
observations suggest the possibility that p21/WAF1 plays
important roles in induction and maintenance of cell cycle
arrests at G2 as well as G1 in B19-infected cells.Materials and methods
Cell lines and transfection
HCT116 cells and HCT116 p21(/) cells (a kind gift
from Dr. B. Vogelstein, Johns Hopkins University School
of Medicine, Baltimore, USA) were maintained in Dul-
becco’s modified Eagle’s medium (DMEM) with 10% fetal
calf serum and incubated at 378C. UT7/Epo-S1 cells,
which are highly susceptible to B19 virus infection (Morita
et al., 2001), were propagated in Isocove’s modified
Dulbecco’s medium containing 10% fetal calf serum and
2 U/ml recombinant erythropoietin (Epo) (a gift from Kirin
Brewery Pharmaceutical Research Laboratory, Tokyo,
Japan). The 293T cells were grown at 378C in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal
calf serum. For luciferase assays and cell cycle analyses,
subconfluent cells were transfected with the indicated
plasmids using FuGENE 6 (Roche Diagnostics, Indian-
apolis, Ind.). The amounts of reporter and effector
plasmids used for the luciferase assays are described in
the text. For cell cycle analyses, transient transfection of
UT7/Epo-S1 cells was performed with the Amaxa electro-
poration gene transfer system (Amaxa GmbH, Berlin,
Germany).
Plasmids and site-directed mutagenesis
The wild-type NS1 expression plasmid, pMP6-NS1, and
the control vector plasmid, pMP6, were described previ-
ously (Morita et al., 2003). The human wild-type p21/
WAF1/Cip1 promoter luciferase fusion plasmid, pWWP-
Luc, was a gift from Dr. B. Vogelstein (el-Deiry et al.,1993). A series of p21/WAF1/Cip1 promoter luciferase
plasmids, pM-Sp1, pM-Sp3, and pG5-Luc were gifts from
Dr. T. Sakai (Nakano et al., 1997). pEVR2/Sp1 and pRC/
CMV/Sp3 are expression vectors for Sp1 and Sp3,
respectively, provided by Dr. G. Suske (Hagen et al.,
1994). pRc/RSV/CBP-HA is a CBP expression vector
provided by Dr. T. Nakajima (St. Marianna University
School of Medicine, Kanagawa, Japan).
The QuikChange XL Site-Directed Mutagenesis Kit
(Stratagene, La Jolla, CA) was used to engineer a lysine-
to-glutamate (K334E) mutation into the wild-type NS1
expression vector, pMP6-NS1, with the following oligonu-
cleotide primers: 5V-CCGCCAAGTACAGGAGAAA-
CAAACTTGGCAATG-3 V ( fo rward pr imer ) and
5V-CATTGCCAAGTTTGTTTCTCCTGTACTTGGCGG-3V
(reverse primer) for K334E. We named this construct
pMP6-NS1-KE. Successful mutagenesis of the plasmids
was verified by sequencing.
Cell cycle analysis
Cell cycle analyses were performed as described pre-
viously (Darzynkiewicz et al., 1992). In brief, cells were
transfected with plasmids and cultured for the indicated
times. After the cells were washed twice with phosphate-
buffered saline (PBS), they were suspended in propidium
iodide (PI) solution (50 Ag/ml PI, 0.1% sodium citrate, 0.2%
NP-40, 0.05 mg/ml RNase), then incubated for 30 min at
48C. PI-positive cells in the G0/G1 and G2/M fractions were
counted with a FACScan fluorescence-activated cell sorter
(FACS; BD Biosciences, Franklin Lakes, NJ). To detect G1-
arrested cells, the cells were treated with 20 AM paclitaxel, a
mitotic inhibitor (Wako Pure Chemical Industries, Ltd.,
Osaka, Japan) for 24 h before staining with PI.
Western blotting
Western blot analyses were carried out as described
elsewhere (Asao et al., 1997). In brief, cells were lysed in an
aliquot of whole-cell extraction buffer [10 mM NaHPO4, 1
mM EDTA, 1 mM dithiothreitol (DTT), 400 mM KCl, 10%
glycerol, 5 Ag/ml aprotinin, 10 Ag/ml leupeptin, 2 AM
pepstatin, 1 mM phenylmethylsulfonyl fluoride, 5 mM NaF,
1 mM Na3VO4]. After one freeze-and-thaw cycles, cell
lysates were spun in a microcentrifuge at 14,000 rpm for 20
min to remove cell debris. Ten micrograms of protein from
each supernatant was separated by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS–PAGE) with 10–
12% polyacrylamide, and the proteins were transferred to
nitrocellulose membrane (Millipore, Billerica, MA) by
electroblotting for 1.5 h at 25 V in an ATTO semidry
blotting system. The membrane was then incubated for 1 h
in blocking buffer [Tris-buffered saline (TBS) solution
containing 1% Tween 20 and 5% bovine serum albumin]
and further incubated for 3 h at room temperature with the
following antibodies: anti-NS1 monoclonal antibody
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B19 virus (Morita et al., 2003), anti-a-tubulin MAb (Sigma-
Aldrich Fine Chemicals, St. Louis, Mo.), and anti-p21
antibody (Santa Cruz Biotechnology, Santa Cruz, CA).
Bound antibodies were labeled with horseradish peroxidase-
conjugated anti-mouse antibody, washed extensively, then
visualized with a sensitive enhanced chemiluminescence
detection system (ECL detection kit; Amersham Bioscience
Corp., Piscataway, NJ).
Luciferase assay
Cells were seeded into 6-well plates at a density of 3 
105cells/well, 1 day before transfection. The 293T cells were
transfected with 10 ng of promoter–reporter plasmids, 2 ng
of pRL-null control vector (Promega Corp., Madison, WI),
the indicated amounts of effector constructs, and/or empty
control vectors to adjust the total amount of plasmid DNA so
that it was equal in each well. After 2 days of transfection,
total cell lysates were assayed for luciferase activity using a
luminometer and dual luciferase assay kit (Promega Corp.).
The luciferase activities were normalized against the activity
of the control vector and the protein concentration. Each
experiment was performed at least three times.
Immunoprecipitation
The 293T cells were transfected with an expression
construct for NS1, NS1-KE, or the pMP6 control vector
together with pEVR2/Sp1 or pRC/CMV/Sp3. Forty-eight
hours after transfection, the cells were washed, scraped from
the dish, and collected. Their nuclear extracts were prepared
as described previously (Andrews and Faller, 1991).
Samples were incubated with protein A-Sepharose beads
for 1 h at 48C, followed by incubation with protein A-
Sepharose beads conjugated with anti-NS1 MAb, anti-Sp1,
or anti-Sp3 antibody (Santa Cruz Biotechnology) for 6 h at
48C. The beads were washed five times with buffer
containing 25 mM Tris–HCl pH 7.5, 140 mM NaCl, 1%
NP-40, 1 mM EDTA, and 10 mM Na4P2O7. The immune
complexes were then eluted by boiling for 5 min and
separated by SDS–PAGE. Aliquots of the nuclear extracts
were directly subjected to SDS–PAGE without immunopre-
cipitation. The subsequent procedures were as described
above in the section on Western blotting.
Electrophoretic mobility shift assay (EMSA)
Single-stranded oligonucleotides were synthesized by
Hokkaido System Science Co., Ltd. (Hokkaido, Japan), and
the complementary sense and antisense strands were then
annealed into double-stranded DNAs and used for EMSA.
The double-stranded DNAs were end-labeled using T4
polynucleotide kinase and [g-32P] ATP. Subsequently, 0.1–
0.2 ng of probes (approximately 2  105 cpm) were
incubated with 6 Ag of nuclear extract on ice for 20 min in15 Al of binding reaction mixture that contained 10 mM
Hepes (pH 7.9), 25 mM NaCl, 1 mM EDTA, 0.25 mM
dithiothreitol, 10% glycerol, 0.5 mM magnesium spermi-
dine, and 30 ng/Al poly(dI-dC). The reaction was stopped by
adding gel loading buffer, and the mixture was immediately
loaded onto a 5% acrylamide–bisacrylamide (79:1) and
0.5 TBE nondenaturing gel at 15 V/cm. The run was
stopped when the bromophenol blue reached the lower
margin of the gel. The antibodies used for the gel supershift
assays were anti-Sp1, anti-Sp3, and anti-NS1 antibodies; 2
Ag/Al antibody was added to the binding reaction mixture,
which was incubated on ice for an additional 1 h before
loading. The oligonucleotide probes, Sp1-3wt and Sp1-5-
6wt, corresponded to the sequences from 92 to 70
and69 to 47 of the wild-type p21/WAF1 promoter,
respectively, and their mutants were Sp1-3mt and Sp1-5-
6mt, respectively (Fig. 3A). Their sequences were as
follows: Sp1-3wt probe: 5V-GAGCGCGGGTCCCG-
CCTCCTTGA-3V; Sp1-3mt probe: 5V-GAGCGCGGGT-




The mammalian expression vector, piGENE hU6
(iGENE Therapeutics, Inc., Ibaraki, Japan), was used for
expression of siRNA in 293T cells. The gene-specific insert
specifies a 21-nucleotide sequence corresponding to nucleo-
tides 950–970 downstream of the transcription start site
(gtaaacagatggcactttgaa) of p21/WAF1. A control vector,
pU6–siRNA–control, was constructed using a 21-nucleotide
sequence (gtgcgctgctggtgccaaccc) with specific homology
to firefly luciferase gene sequence and therefore serves as a
negative control. We constructed these vectors according to
the manufacturer’s instructions. The purified vectors were
digested with EcoRI and HindIII and the fragments were
ligated into the EcoRI and HindIII cloning site in the
pBluescript KS II (+) (Stratagene), respectively. Subse-
quently, the EcoRI and SalI fragments in the pBluescript KS
II (+) were ligated into pMACS Kk.II (Miltenyi Biotec,
Gladbach, Germany). DNA sequence analysis confirmed
the correct sequence. These vectors were referred to as
pMACS–H2Kk–siRNA–p21 and pMACS–H2Kk–siRNA–
control, respectively. Transient transfections to 293T cells
were performed with FuGene 6 (Roche Diagnostics). Cells
were trypsinized 48 h after transfection, resuspended in PBE
(PBS supplemented with 0.5% bovine serum albumin and 5
mM EDTA) buffer, and incubated with MACSelect Kk
MicroBeads (Miltenyi Biotec). H2Kk-positive cells were
enriched using the AutoMACS machine (Miltenyi Biotec)
and the enrichment rates ranged from 70% to 80% (data not
shown). The enriched cell fractions were then cultured again
for second transfection.
The p53 gene-specific sequence (gactccagtggtaatctac)
and nonspecific sequence (gaattcatctcagcgcgta) were
A. Nakashima et al. / Virology 329 (2004) 493–504 503inserted into pRNAT-U6.1/Neo (GenScript Corp., Piscat-
away, NJ) (Brummelkamp et al., 2002). We created siRNA
expression vector against p53, pRNAT-U6.1/Neo-p53-1.
These vectors were transiently transfected into HCT116
cells with Lipofectamine 2000 (Invitrogen Corp., Carlsbad,
CA). After trypsinization, cells, which the GFP positive,
were obtained by using a BD FACSAria cell sorter (BD
Biosciences). Western blotting showed that the specific
inhibition of p53 expression was approximately 75% in cells
transfected with pRNAT-U6.1/Neo-p53-1, as compared with
control vector (data not shown).Acknowledgments
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